Omacetaxine mepesuccinate: Interim Phase II/III data

ChemGenex reported additional interim data from 25 evaluable CML patients in an ongoing Phase II/III trial. In 15 chronic phase patients, 13 had hematologic or cytogenic responses, including 9 patient...